Rapid resolution of symptoms with moxifloxacin therapy in 7223 patients with acute exacerbation of chronic bronchitis: Comparison with prior macrolide treatment

Clinical Drug Investigation

Volumn 22, Issue 10, 2002, Pages 641-651

  Bauer, T ^a   Landen, H ^b  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ANTITUSSIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; BRONCHODILATING AGENT; CLARITHROMYCIN; ERYTHROMYCIN; EXPECTORANT AGENT; MACROLIDE; MOXIFLOXACIN; ROXITHROMYCIN; TETRACYCLINE;

ABDOMINAL PAIN; ADULT; AGED; ANAPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; CHILL; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; COUGHING; DIARRHEA; DISEASE EXACERBATION; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; FEMALE; FEVER; FOLLOW UP; GENERAL PRACTICE; GERMANY; HUMAN; HYPOTENSION; LUNG AUSCULTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OBSERVATION; PHYSICIAN; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SELF EVALUATION; SHORT COURSE THERAPY; SPUTUM; SYMPTOM; THORAX PAIN; TREATMENT OUTCOME; VERTIGO;

EID: 0036394263     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200222100-00001     Document Type: Article

References (51)

1. Doll H, Grey-Amante P, Duprat-Lomon I, et al. Quality of life in acute exacerbation of chronic bronchitis: results from a German population study. Respir Med 2002; 96: 39-51
2. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204
3. Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 2000; 117: 380S-5S
4. Hirschmann JV. Do bacteria cause exacerbations of COPD? Chest 2000; 118: 193-203
5. Murphy TF, Sethi S, Niederman MS. The role of bacteria in exacerbations of COPD: a constructive view. Chest 2000; 118: 204-9
6. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418-22
7. Hurd S. The impact of COPD on lung health worldwide: epidemiology and incidence. Chest 2000: 117: 1S-4S
8. National Institutes of Health, NHLBI. Morbidity & Mortality: 2002 chart book on cardiovascular, lung, and blood diseases. Available from URL: http://www.nhlbi.nih.gov/resources/ docs/cht-book.htm [Accessed July 2002]
9. Sethi S, Murphy TF. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin Microbiol Rev 2001; 14: 336-63
10. Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12- 8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother 1997; 40: 639-51
11. Fass RJ. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone. Antimicrob Agents Chemother 1997; 41: 1818-24
12. Souli M, Wennersten CB, Eliopoulos GM. In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens. Int J Antimicrob Agents 1998; 10: 23-30
13. Weiss K, Laverdiere M, Restieri C. Comparative activity of trovafloxacin and Bay 12-8039 against 452 clinical isolates of Streptococcus pneumoniae. J Antimicrob Chemother 1998; 42: 523-5
14. Biedenbach DJ, Barrett MS, Croco MA, et al. BAY 12-8039, a novel fluoroquinolone: activity against important respiratory tract pathogens. Diagn Microbiol Infect Dis 1998; 32: 45-50
15. Reinert RR, Schlaeger JJ, Lutticken R. Moxifloxacin: a comparison with other antimicrobial agents of in-vitro activity against Streptococcus pneumoniae. J Antimicrob Chemother 1998; 42: 803-6
16. Rubio MC, Goni P, Vergara Y, et al. Susceptibility of penicillin-resistant and penicillin-susceptible Streptococcus pneumoniae to newer antimicrobial agents. J Chemother 1999; 11: 191-4
17. Blondeau JM, Laskowski R, Bjarnason J, et al. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms. Int J Antimicrob Agents 2000; 14: 45-50
18. Andrews J, Honeybourne D, Jevons G, et al. Penetration of Bay 12-8039 into bronchial mucosa, epithelial lining [Abstract no. A29]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 1998 Sep 24-27: San Diego (CA), USA.
19. Muller M, Stass H, Brunner M, et al. Penetration of moxifloxacin into peripheral compartments in humans. Antimicrob Agents Chemother 1999; 43: 2345-9
20. Blondeau JM. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones. J Antimicrob Chemother 1999; 43 Suppl B: 1-11
21. Lode H, Garau J. Improving care for patients with respiratory tract infections. J Chemother 2002; 14 Suppl. 2: 22-8
22. Wilson R, Kubin R, Ballin I, et al. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999; 44: 501-13
23. Chodosh S, DeAbate CA, Haverstock D, et al. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Respir Med 2000; 94: 18-27
24. Schaberg T, Ballin I, Huchon G, et al. A multinational, multi-centre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis. J Int Med Res 2001; 29: 314-28
25. Kreis SR, Herrera N, Golzar N, et al. A comparison of moxifloxacin and azithromycin in the treatment of acute exacerbations of chronic bronchitis. J Clin Outcomes Management 2000; 7: 33-7
26. DeAbate CA, Mathew CP, Warner JH, et al. The safety and efficacy of short course (5-day) moxifloxacin vs azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis. Respir Med 2000; 94: 1029-37
27. Urueta J, Ariza J, De Brito A, et al. Safety and efficacy of moxifloxacin vs levofloxacin in the treatment of AECB [abstract]. Clin Microbiol Infect 2001; 7 Suppl. 1: 168
28. Hautamaki D, Bruya T, Kureishi A, et al. Short course (5-day) moxifloxacin versus 7-day levofloxacin therapy for treatment of acute exacerbations of chronic bronchitis. Todays Ther Trends 2001; 19: 117-36
29. Lorenz J, Thate-Waschke IM, Mast O, et al. Treatment outcomes in acute exacerbations of chronic bronchitis: comparison of macrolides and moxifloxacin from the patient perspective. J Int Med Res 2001; 29: 74-86
30. Landen H, Moller M, Tillotson GS, et al. Clinical experience in Germany of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone, moxifloxacin. J Int Med Res 2001; 29: 51-60
31. Lorenz J, Busch W, Thate-Waschke IM. Moxifloxacin in acute exacerbations of chronic bronchitis: clinical evaluation and assessment by patients. J Int Med Res 2001; 29: 61-73
32. Miravitlles M, Ros F, Cobos A, et al. The efficacy of moxifloxacin in acute exacerbations of chronic bronchitis: a Spanish physician and patient experience. Int J Clin Pract 2001; 55: 437-41
33. O'Hare M, Harding I. Levofloxacin for treatment of acute bacterial exacerbations of chronic bronchitis: advantages over currently available therapies [abstract]. J Antimicrob Chemother 2001; 47 (Suppl. 1): 47
34. Landen H, Bauer T. Efficacy, onset of action and tolerability of moxifloxacin in patients with community-acquired pneumonia: results of a postmarketing surveillance study. Clin Drug Invest 2001; 21: 801-8
35. Fogarty C, Grossman C, Williams J, et al. Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia. Infect Med 1999; 16: 748-63
36. Höffken G, Meyer HP, Winter J, et al. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. Respir Med 2001; 95: 553-64
37. Petitpretz P, Arvis P, Marel M, et al. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild- to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest 2001; 119: 185-95
38. Reinert RR, Simic S, Al-Lahham A, et al, Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients with respiratory tract infections in Germany from 1998 to 1999: results of a national surveillance study. J Clin Microbiol 2001; 39: 1187-9
39. Reinert RR, Al-Lahham A, Lemperle M, et al. Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany. J Antimicrob Chemother 2002; 49: 61-8
40. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S77-121
41. Clavo-Sanchez AJ, Giron-Gonzalez JA, Lopez-Prieto D, et al. Multivariate analysis of risk factors for infection due to penicillin- resistant and multidrug-resistant Streptococcus pneumoniae: a multicenter study. Clin Infect Dis 1997; 24: 1052-9
42. Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000; 343: 1917-24
43. Doern GV, Heilmann KP, Huynh HK, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000: including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 2001; 45: 1721-9
44. Jones ME, Karlowsky JA, Blosser-Middleton R, et al. Apparent plateau in beta-lactamase production among clinical isolates of Haemophilus influenzae and Moraxella catarrhalis in the United States: results from the LIBRA Surveillance initiative. Int J Antimicrob Agents 2002; 19: 119-23
45. Felmingham D, Reinert RR. Prevalence of antibiotic resistance among European respiratory tract pathogens (1999/2000). Presentation No. 685. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2001 Dec 1619; Chicago, Illinois, USA.
46. Bell JM, Turnidge JD, Jones RN. Antimicrobial resistance trends in community-acquired respiratory tract pathogens in the Western Pacific Region and South Africa: report from the SENTRY antimicrobial surveillance program, (1998-1999) including an in vitro evaluation of BMS284756. Int J Antimicrob Agents 2002; 19: 125-32
47. Sahm DF, Karlowsky JA, Kelly LJ, et al. Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis. Antimicrob Agents Chemother 2001; 45: 1037-42
48. Gatifloxacin (Tequin®) prescribing information. Bristol-Myers Squibb Company, Princeton, NJ, USA. Revised October 2001. Available from URL: http://www.bms.com/medicines/data/[Accessed May 2002]
49. Levofloxacin (Levaquin®) prescribing information. Ortho-McNeil Pharmaceutical, Inc., Raritan, NJ, USA. Revised January 2002. Available from URL: http://www.ortho-mcneil.com/products [Accessed May 2002]
50. Zhanel GG, Ennis K, Vercaigne L, et al. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs 2002; 62: 13-59
51. Mandell L, Choudhri SH, Kubin R. Safety assessment of sequential IV/PO moxifloxacin in the treatment of patients with community-acquired pneumonia (CAP). Poster presentation at the 11th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 2001 Apr 1-4; Istanbul, Turkey